These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 21395124)

  • 1. [Use of LAK-cells and systemic chemotherapy with hyperthermia in the management of chemo-resistant tumors].
    Ismail-Zade RS; Zhavrid EA; Aleĭnikova OV; Potapnev MP; Belevtsev MV; Isaĭkina IaI; Vashkevich EP; Savitskiĭ VP
    Vopr Onkol; 2010; 56(6):681-6. PubMed ID: 21395124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Lymphokine-activated killer (LAK) therapy for metastatic renal cell carcinoma].
    Nakano E
    Hinyokika Kiyo; 1992 Nov; 38(11):1305-9. PubMed ID: 1485586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Lymphokine-activated killer (LAK) therapy for advanced renal cell carcinoma: clinical study on arterial LAK therapy and experimental study on LAK cell activity].
    Hayakawa M
    Hinyokika Kiyo; 1992 Nov; 38(11):1311-8. PubMed ID: 1485587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperthermia for the treatment of patients with malignant germ cell tumors: a phase I/II study in ten children and adolescents with recurrent or refractory tumors.
    Wessalowski R; Kruck H; Pape H; Kahn T; Willers R; Göbel U
    Cancer; 1998 Feb; 82(4):793-800. PubMed ID: 9477114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Whole body hyperthermia in adjuvant therapy of children with renal cell carcinoma.
    Ismail-Zade RS; Zhavrid EA; Potapnev MP
    Pediatr Blood Cancer; 2005 Jun; 44(7):679-81. PubMed ID: 15700247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intralesional lymphokine-activated killer cells as adjuvant therapy for primary glioblastoma.
    Dillman RO; Duma CM; Ellis RA; Cornforth AN; Schiltz PM; Sharp SL; DePriest MC
    J Immunother; 2009; 32(9):914-9. PubMed ID: 19816190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Studies on lymphokine-activated killer (LAK) cell: accumulation in tumor tissue and the therapeutic effects of adoptive immunotherapy].
    Wakizaka Y
    Hokkaido Igaku Zasshi; 1992 Jul; 67(4):475-87. PubMed ID: 1330859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase III randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma.
    Kimura H; Yamaguchi Y
    Cancer; 1997 Jul; 80(1):42-9. PubMed ID: 9210707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Adoptive immunotherapy in patients with medulloblastoma by LAK cells].
    Shimizu K; Tamura K; Yamada M; Okamoto Y; Miyao Y; Park K; Matsui Y; Hayakawa T; Takimoto H; Mogami H
    No To Shinkei; 1989 Oct; 41(10):991-5. PubMed ID: 2605046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Whole body hyperthermia supplemented with urotropin in the treatment of malignant tumors.
    Ismail-Zade RS
    Exp Oncol; 2005 Mar; 27(1):61-4. PubMed ID: 15812360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment results in children and adolescents with loco-regional recurrences of abdominal germ cell tumors (GCTs): a pilot-study with PEI chemotherapy and regional deep hyperthermia (RHT) in comparison to a matched cohort.
    Wessalowski R; Blohm M; Calaminus G; Engert J; Harms D; Krause I; Kruck H; Grüttner HP; Pape H; Göbel U
    Klin Padiatr; 1997; 209(4):250-6. PubMed ID: 9293458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term outcome of immunotherapy for patients with refractory pancreatic cancer.
    Nakamura M; Wada J; Suzuki H; Tanaka M; Katano M; Morisaki T
    Anticancer Res; 2009 Mar; 29(3):831-6. PubMed ID: 19414316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy with interleukin 2 with or without lymphokine-activated killer cells after autologous bone marrow transplantation for malignant lymphoma: a feasibility trial.
    Benyunes MC; Higuchi C; York A; Lindgren C; Thompson JA; Buckner CD; Fefer A
    Bone Marrow Transplant; 1995 Aug; 16(2):283-8. PubMed ID: 7581149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of different immunotherapy approaches toward treatment of doxorubicin-resistant and doxorubicin-sensitive transplantable rhabdomyosarcoma.
    Belova OB; Vinnichuk UD; Shlakhovenko VA; Berezhnaya NM
    Exp Oncol; 2007 Dec; 29(4):272-6. PubMed ID: 18199982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 41.8 degrees C whole body hyperthermia as an adjunct to chemotherapy induces prolonged T cell activation in patients with various malignant diseases.
    Atanackovic D; Nierhaus A; Neumeier M; Hossfeld DK; Hegewisch-Becker S
    Cancer Immunol Immunother; 2002 Dec; 51(11-12):603-13. PubMed ID: 12439605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy with lymphokine-activated natural killer cells and recombinant interleukin-2: a feasibility trial in metastatic renal cell carcinoma.
    Hercend T; Farace F; Baume D; Charpentier F; Droz JP; Triebel F; Escudier B
    J Biol Response Mod; 1990 Dec; 9(6):546-55. PubMed ID: 2074441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Susceptibility of human leukemia to allogeneic and autologous lymphokine-activated killer cell activity: analysis of 252 samples.
    Teichmann JV; Ludwig WD; Thiel E
    Nat Immun; 1992; 11(3):117-32. PubMed ID: 1392400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymphokine-activated killer (LAK) cell generation from peripheral blood stem cells by in vitro incubation with low-dose interleukin-2 plus granulocyte-macrophage colony-stimulating factor.
    Herrera C; García-Pérez MJ; Ramirez R; Martín C; Alvarez MA; Martinez F; Gómez P; García-Castellano JM; Torres A
    Bone Marrow Transplant; 1997 Mar; 19(6):545-51. PubMed ID: 9085733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Therapeutic effects of high dose chemotherapy combined with autologous peripheral blood stem cell transplantation for neural ectodermal solid tumor originated from neural crest in children].
    Zhang WL; Zhang Y; Huang DS; Wang YZ; Zhu X; Hong L; Li P; Zhang PW; Zhou Y
    Zhongguo Dang Dai Er Ke Za Zhi; 2010 Apr; 12(4):244-7. PubMed ID: 20416211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin 2 and lymphokine-activated killer cell therapy: analysis of a bolus interleukin 2 and a continuous infusion interleukin 2 regimen.
    Clark JW; Smith JW; Steis RG; Urba WJ; Crum E; Miller R; McKnight J; Beman J; Stevenson HC; Creekmore S
    Cancer Res; 1990 Nov; 50(22):7343-50. PubMed ID: 2224862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.